Hypertension in Chronic Glomerulonephritis
- PMID: 26848302
- PMCID: PMC4737660
- DOI: 10.5049/EBP.2015.13.2.41
Hypertension in Chronic Glomerulonephritis
Abstract
Chronic glomerulonephritis (GN), which includes focal segmental glomerulosclerosis and proliferative forms of GN such as IgA nephropathy, increases the risk of hypertension. Hypertension in chronic GN is primarily volume dependent, and this increase in blood volume is not related to the deterioration of renal function. Patients with chronic GN become salt sensitive as renal damage including arteriolosclerosis progresses and the consequent renal ischemia causes the stimulation of the intrarenal renin-angiotensin-aldosterone system(RAAS). Overactivity of the sympathetic nervous system also contributes to hypertension in chronic GN. According to the KDIGO guideline, the available evidence indicates that the target BP should be ≤140mmHg systolic and ≤90mmHg diastolic in chronic kidney disease patients without albuminuria. In most patients with an albumin excretion rate of ≥30mg/24 h (i.e., those with both micro-and macroalbuminuria), a lower target of ≤130mmHg systolic and ≤80mmHg diastolic is suggested. The use of agents that block the RAAS system is recommended or suggested in all patients with an albumin excretion rate of ≥30mg/ 24 h. The combination of a RAAS blockade with a calcium channel blocker and a diuretic may be effective in attaining the target BP, and in reducing the amount of urinary protein excretion in patients with chronic GN.
Keywords: Chronic glomerulonephritis; RAAS blockade; Volume dependent.
Similar articles
-
Effects of Dietary Sodium Restriction in Kidney Transplant Recipients Treated With Renin-Angiotensin-Aldosterone System Blockade: A Randomized Clinical Trial.Am J Kidney Dis. 2016 Jun;67(6):936-44. doi: 10.1053/j.ajkd.2015.11.026. Epub 2016 Jan 21. Am J Kidney Dis. 2016. PMID: 26803690 Clinical Trial.
-
Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.Trials. 2018 Feb 12;19(1):101. doi: 10.1186/s13063-017-2343-3. Trials. 2018. PMID: 29433578 Free PMC article.
-
Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease?Kidney Int. 2013 Mar;83(3):377-83. doi: 10.1038/ki.2012.425. Epub 2013 Jan 16. Kidney Int. 2013. PMID: 23325075 Review.
-
Urinary renin, but not angiotensinogen or aldosterone, reflects the renal renin-angiotensin-aldosterone system activity and the efficacy of renin-angiotensin-aldosterone system blockade in the kidney.J Hypertens. 2011 Nov;29(11):2147-55. doi: 10.1097/HJH.0b013e32834bbcbf. J Hypertens. 2011. PMID: 21941204
-
[The role of tubulointerstitial changes in progression of kidney function failure in patients with chronic glomerulonephritis (GN)].Przegl Lek. 1996;53(5):443-53. Przegl Lek. 1996. PMID: 8754411 Review. Polish.
Cited by
-
DOME: Directional medical embedding vectors from Electronic Health Records.J Biomed Inform. 2025 Feb;162:104768. doi: 10.1016/j.jbi.2024.104768. Epub 2025 Jan 2. J Biomed Inform. 2025. PMID: 39755324
-
Prognostic significance of circulating microparticles in IgA nephropathy.Int Urol Nephrol. 2024 Mar;56(3):1071-1081. doi: 10.1007/s11255-023-03743-6. Epub 2023 Aug 24. Int Urol Nephrol. 2024. PMID: 37615844
-
Underlying Mechanisms and Treatment of Hypertension in Glomerular Diseases.Curr Hypertens Rep. 2024 Mar;26(3):119-130. doi: 10.1007/s11906-023-01287-9. Epub 2023 Nov 20. Curr Hypertens Rep. 2024. PMID: 37982994 Review.
-
Mechanism of herbal medicine on hypertensive nephropathy (Review).Mol Med Rep. 2021 Apr;23(4):234. doi: 10.3892/mmr.2021.11873. Epub 2021 Feb 4. Mol Med Rep. 2021. PMID: 33537809 Free PMC article. Review.
-
The issue of atherosclerosis in primary glomerulonephritis.J Bras Nefrol. 2024 Jan-Mar;46(1):3-4. doi: 10.1590/2175-8239-JBN-2023-E015en. J Bras Nefrol. 2024. PMID: 38078835 Free PMC article. No abstract available.
References
-
- Nachman PH, Jennette JC, Falk RJ. Primary glomerular disease. In: Brenner BM, Rector FC Jr, editors. The kidney. 10th ed. Philadelphia: Saunders; 2011. pp. 1101–1191.
-
- Orofino L, Quereda C, Lamas S, Orte L, Gonzalo A, Mampaso F, et al. Hypertension in primary chronic glomerulonephritis: analysis of 288 biopsied patients. Nephron. 1987;45:22–26. - PubMed
-
- Csiky B, Kovács T, Wágner L, Vass T, Nagy J. Ambulatory blood pressure monitoring and progression in patients with IgA nephropathy. Nephrol Dial Transplant. 1999;14:86–90. - PubMed
-
- Kaplan NM. Clinical Hypertension. 7th ed. Baltimore: Williams & Wilkins; 1998. Renal parenchymal hypertension; pp. 281–299.
-
- Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension. 2004;43:699–706. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous